AURA / Aura Biosciences, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC

Exhibit 99.1 Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 Million Equity Financing; Cash Position Expected to Fund Operations into the First Half of 2027 BOS

Amended and Restated Non-Employee Director Compensation Policy.

Exhibit 10.1 AURA BIOSCIENCES, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Aura Biosciences, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40971 AURA BIOSCIENCES, INC.

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 8.01 Other Events.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission

Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Innovating the future of cancer care to cure patients and preserve organ function August 2025 Exhibit 99.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission Fi

Underwriting Agreement, dated May 15, 2025, by and between the Company and Leerink Partners, as representative of the several underwriters named therein

Exhibit 1.1 AURA BIOSCIENCES, INC. 11,735,565 Shares of Common Stock Pre-Funded Warrants to Purchase 3,571,435 Shares of Common Stock Common Stock Warrants to Purchase 3,826,750 Shares of Common Stock UNDERWRITING AGREEMENT May 15, 2025 LEERINK PARTNERS LLC  As Representative of the several Underwriters c/o Leerink Partners LLC 53 State Street 40th Floor Boston, Massachusetts 02109 Dear Sirs and M

Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Exhibit 99.1 May 2025 Innovating the future of cancer care to cure patients and preserve organ function Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as may , anticipate , believe , co

11,735,565 Shares of Common Stock Pre-Funded Warrants to Purchase up to 3,571,435 Shares of Common Stock Common Warrants to Purchase up to 3,826,750 Shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-278253 Prospectus Supplement (To Prospectus Dated April 5, 2024) 11,735,565 Shares of Common Stock Pre-Funded Warrants to Purchase up to 3,571,435 Shares of Common Stock Common Warrants to Purchase up to 3,826,750 Shares of Common Stock We are offering 11,735,565 shares of our common stock, par value $0.00001 per share, or com

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission Fil

Form of Pre-Funded Warrant to Purchase Common Stock

Exhibit 4.1 The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting

Form of Common Stock Warrant to Purchase Common Stock

Exhibit 4.2 The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting

Employment Offer Letter, dated May 9, 2025, by and between Anthony Gibney and the Registrant.

Exhibit 10.1 May 9, 2025 Anthony Gibney [***] [***] Re: Amended and Restated Offer of Employment Dear Tony, Following up on our discussions, the following represents our offer regarding your employment by Aura Biosciences, Inc. (the “Company”) as a full-time, “at will” employee. This letter agreement is referred to herein as this “Agreement”. This offer and the terms of your employment with the Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

,k UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40971 AURA BIOSCIENCES, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission Fil

Subject to completion, dated May 15, 2025

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-278253 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 S

Exhibit 99.1 Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of Tony Gibney as Chief Financial and Business Officer BOSTON, MA – May 15, 2025 – Aura

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission F

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

Exhibit 99.1 Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors BOSTON, April 2, 2025 (GLOBE NEWSWIRE) - Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Tak

As filed with the Securities and Exchange Commission on March 24, 2025

As filed with the Securities and Exchange Commission on March 24, 2025 Registration No.

Filing Fee Table

Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Aura Biosciences, Inc.

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supp

Exhibit 99.1 Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeline Continues to Advance with Phase 3 CoMpass Trial Actively Enrolling Phase 2 Trial in

List of Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation or Organization Aura Biosciences Securities Corporation Massachusetts Aura Biosciences B.V. Netherlands Aura Biosciences GmbH Germany

Amended and Restated Insider Trading Policy.

Exhibit 19.1 AURA BIOSCIENCES, INC. AMENDED AND RESTATED INSIDER TRADING POLICY This memorandum sets forth the policy of Aura Biosciences, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Amended and Restated Insider Trading Policy (this “Insider Trading Policy”) i

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The summary of the general terms and provisions of the registered securities of Aura Biosciences, Inc. (the “Company,” “we,” “us,” and “our”) set forth below does not purport to be complete. It is subject to and qualified in its entirety by reference to our Tenth Amended

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40971 AURA BIOSCIENCE

Employment Offer Letter between the Registrant and Amy Elazzouzi, dated August 19, 2015.

Exhibit 10.9 August 19, 2015 Amy Elazzouzi [***] [***] Re: Offer of Employment Dear Ms. Elazzouzi: Following up on our discussions, the following represents our offer regarding your employment by Aura Biosciences, Inc. (the "Company") as a full-time, “at will” employee. Your title and position will be Corporate Controller and you will report to the Chief Financial Officer or his designee. The scop

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission F

First Amendment to License Agreement with Clearside Biomedical, Inc., dated February 23, 2022.

Exhibit 10.14 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. FIRST AMENDMENT TO LICENSE AGREEMENT THIS FIRST AMENDMENT TO THE LICENSE AGREEMENT (the “First Amendment

Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Innovating the future of cancer care to cure patients and preserve organ function March 2025 Exhibit 99.

EXHIBIT 1

EX-1 2 ex1.htm EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13G is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of the undersigned without the necessity of filing additional joint acquisition statements.

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13G is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of the undersigned without the necessity of filing additional joint acquisition statements.

AURA / Aura Biosciences, Inc. / Lundbeckfond Invest A/S - SC 13G/A Passive Investment

SC 13G/A 1 tm2427620d15sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aura Biosciences, Inc. (Name of Issuer) Common stock, $0.00001 par value per share (Title of Class of Securities) 05153U107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen

AURA / Aura Biosciences, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm2427061d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 4)* Aura Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (the “Shares”)

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commissio

Executive Severance Plan, and form of participation agreement thereunder.

Exhibit 10.3 Aura Biosciences, Inc. Executive Severance Plan 1. Purpose. Aura Biosciences, Inc., a Delaware corporation (the “Company”), considers it essential to the best interests of its stockholders to foster the continuous employment of key management personnel. The Board of Directors of the Company (the “Board”) recognizes, however, that, as is the case with many publicly-held corporations, t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

,k UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40971 AURA BIOSCIENCES, INC.

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling

Exhibit 99.1 Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe Multiple Clinical Complete Responses Observed with Single Low Dose of Bel-sar in Ongoing Phase 1 Trial in Non-Muscle I

Transition and Release Agreement, dated September 25, 2024, by and between Julie Feder and the Registrant.

Exhibit 10.1 September 25, 2024 PERSONAL AND CONFIDENTIAL Julie Feder Re: Transition and Release Agreement Dear Ms. Feder: This letter confirms your resignation from employment with Aura Biosciences, Inc. (the “Company”), effective October 25, 2024. As you know, your employment relationship with the Company is governed by your offer letter with the Company dated August 10, 2018 (the “Offer Letter”

Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Innovating the future of cancer care to cure patients and preserve organ function November 2024 Exhibit 99.

AURA / Aura Biosciences, Inc. / Adage Capital Management, L.P. Passive Investment

SC 13G/A 1 p24-3041sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)*, ** Aura Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05153U107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropri

Resignation and Consulting Agreement, dated September 25, 2024, by and between Julie Feder and the Registrant.

Exhibit 10.2 September 25, 2024 PERSONAL AND CONFIDENTIAL Julie Feder Re: Resignation and Consulting Agreement Dear Ms. Feder: This letter confirms your resignation from your employment with Aura Biosciences, Inc. (the “Company”) effective on October 25, 2024 (the “Resignation Date”). The Company is also offering you the opportunity to enter into a consulting relationship with the Company followin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 Aura Biosciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial Clinical Complete Responses Observed in 4 out of 5 Patients in

EX-99.1 Exhibit 99.1 Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Prof

Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

EX-99.2 Exhibit 99.2 To innovate the future of cancer care to cure patients and preserve organ function October 17, 2024 1 Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as may , antici

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commissi

Regulation FD Disclosure, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commissi

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First- Line Treatment for Early-Stage Choroidal Melanoma Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety

Exhibit 99.1 Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First- Line Treatment for Early-Stage Choroidal Melanoma Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders Today at 8:00 am ET BOSTON, MA – September 1

Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Exhibit 99.2 September 2024 Innovating the future of cancer care to cure patients and preserve organ function Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as may , anticipate , believ

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024 Phase 2 E

Exhibit 99.1 Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024 Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-stage Choroidal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

,k UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40971 AURA BIOSCIENCES, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission

Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Corporate Presentation August 2024 Exhibit 99.2 Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "may", "anticipate", "believe", "could', "expect", "should", "plan", "intend", "estimat

Tenth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect, as amended by the Certificate of Amendment, dated June 20, 2024 (incorporated by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40971) filed on August 8, 2024).

Exhibit 3.1 TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AURA BIOSCIENCES, INC. Aura Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Aura Biosciences, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of

Amended and Restated Non-Employee Director Compensation Policy.

Exhibit 10.1 AURA BIOSCIENCES, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Aura Biosciences, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Compa

Certificate of Amendment to Tenth Amended and Restated Certificate of Incorporation of the Registrant.

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AURA BIOSCIENCES, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Aura Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The Corporation was originally incorpo

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2023 OR ☐

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM       TO       Commission File

Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Exhibit 99.1 Corporate Presentation June 2024 Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as may , anticipate , believe , could', expect , should , plan , intend , estimate , will ,

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 4, 2024 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commission Fil

Employment Offer Letter, dated March 12, 2024, by and between Conor Kilroy and the Registrant.

Exhibit 10.1 March 12, 2024 Conor Kilroy [***] [***] Re: Offer of Employment Dear Conor, Following up on our discussions, the following represents our offer regarding your employment by Aura Biosciences, Inc. (the “Company”) as a full-time, “at will” employee. Your title and position will be General Counsel and Secretary and will report to the Chief Executive Officer. 1. Salary and Expenses: Your

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

,k UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40971 AURA BIOSCIENCES, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission Fil

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early

Exhibit 99.1 Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, MA – May 9, 2024 – Aura Bioscien

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 12, 2024 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commission F

VIA EDGAR

VIA EDGAR April 3, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40971 AURA BIOSCIENCE

Amended and Restated Insider Trading Policy

Exhibit 19.1 AURA BIOSCIENCES, INC. AMENDED AND RESTATED Insider Trading POLICY This memorandum sets forth the policy of Aura Biosciences, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Amended and Restated Insider Trading Policy (this “Insider Trading Policy”) i

As filed with the Securities and Exchange Commission on March 27, 2024

S-8 As filed with the Securities and Exchange Commission on March 27, 2024 Registration No.

Compensation Recovery Policy

Exhibit 97.1 AURA BIOSCIENCES, INC. COMPENSATION RECOVERY POLICY Adopted as of September 26, 2023 Aura Biosciences, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Aura Biosciences, Inc.

As filed with the Securities and Exchange Commission on March 27, 2024

S-3 Table of Contents As filed with the Securities and Exchange Commission on March 27, 2024 Registration No.

Filing Fee Table

EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Aura Biosciences, Inc.

Form of Subordinated Indenture between Registrant and one or more trustees to be named

Exhibit 4.6 AURA BIOSCIENCES, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Cert

Form of Senior Indenture between Registrant and one or more trustees to be named

Exhibit 4.5 AURA BIOSCIENCES, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certifi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission F

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDA Data Expected

Exhibit 99.1 Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDA Data Expected Mid-2024 from Ongoing Phase 1 Trial in Bladder Cancer (Non-Muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer) Strong Cash

Description of Securities

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The summary of the general terms and provisions of the registered securities of Aura Biosciences, Inc. (the “Company,” “we,” “us,” and “our”) set forth below does not purport to be complete. It is subject to and qualified in its entirety by reference to our Tenth Amended

Employment Offer Letter, dated August 10, 2023, by and between Mark Plavsic and the Registrant

Exhibit 10.17 August 8, 2023 Mark Plavsic 12305 Creekview Drive San Diego, CA. 92128 Re: Offer of Employment Dear Mark, Following up on our discussions, the following represents our offer regarding your employment by Aura Biosciences, Inc. (the “Company”) as a full-time, “at will” employee. Your title and position will be Chief Technical Officer and will report to the Chief Executive Officer or he

List of Subsidiaries of Registrant

Exhibit 21.1 List of Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation or Organization Aura Biosciences Securities Corporation Massachusetts Aura Biosciences B.V. Netherlands

AURA / Aura Biosciences, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Aura Biosciences, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (the “Shares”) (Title of Class of Securities) 05153U107

AURA / Aura Biosciences, Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - AURA BIOSCIENCES, INC. Passive Investment

SC 13G/A 1 p24-0385sc13ga.htm AURA BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aura Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05153U107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 Aura Biosciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commission

Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Corporate Presentation January 2024 Exhibit 99.1 Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "may", "anticipate", "believe", "could', "expect", "should", "plan", "intend", "estima

AURA / Aura Biosciences Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment

SC 13G/A 1 sc13g-aura.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aura Biosciences, Inc. (Name of Issuer – as specified in its charter) Common Stock, $0.00001 par value per share (Title of Class of Securities) 05153U107 (CUSIP Number) November 30, 2023 (Date of Event which Requires Filing of this S

Underwriting Agreement, dated as of November 6, 2023, by and between the Company, Leerink Partners, Cowen and Evercore ISI, as representatives of the several underwriters named therein

Exhibit 1.1 11,000,000 Shares AURA BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT November 6, 2023 Leerink Partners LLC Cowen and Company, LLC Evercore Group L.L.C. As Representatives of the several Underwriters c/o Leerink Partners LLC 53 State Street 40th Floor Boston, Massachusetts 02109 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Evercore Group L.L.C. 55

Transition and Release Agreement, dated November 6, 2023, by and between Cadmus Rich and the Registrant.

Exhibit 10.4 PERSONAL AND CONFIDENTIAL Dr. Cadmus Rich Re: Transition and Release Agreement Dear Dr. Rich: This letter confirms your resignation from employment with Aura Biosciences, Inc. (the “Company”), effective November 7, 2023. As you know, your employment relationship with the Company is governed by your offer letter with the Company dated October 6, 2017 (the “Offer Letter”). As specified

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

,k UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40971 AURA BIOSCIENCES, INC.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission

Form of Lock-Up Agreement

EX-99 2 p23-2746exhibit99.htm LOCK-UP AGREEMENT EXHIBIT E Form of Lock-Up Agreement November 5, 2023 LEERINK PARTNERS LLC COWEN AND COMPANY, LLC EVERCORE GROUP, L.L.C. As Representatives of the several Underwriters c/o Leerink Partners LLC 53 State Street 40th Floor Boston, Massachusetts 02109 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Evercore Group, L.L.C. 55 Ea

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical Trial Positive Clinical Efficac

Exhibit 99.1 Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical Trial Positive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial with Suprachoroidal Administration Presen

AURA / Aura Biosciences Inc / Matrix Capital Management Company, LP - AURA BIOSCIENCES, INC. Activist Investment

SC 13D/A 1 p23-2746sc13da.htm AURA BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aura Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05153U107 (CUSIP Number) Joseph Downing Matrix Capital Management Company LP Bay Colony Corporate C

Consulting Agreement, dated September 28, 2023, by and between Cadmus Rich and the Registrant.

Exhibit 10.3 PERSONAL AND CONFIDENTIAL Dr. Cadmus Rich Re: Resignation and Consulting Agreement Dear Dr. Rich: This letter confirms your resignation from your employment with Aura Biosciences, Inc. (the “Company”) effective on November 7, 2023 (the “Resignation Date”). The Company is also offering you the opportunity to enter into a consulting relationship with the Company following the Resignatio

Transition and Release Agreement, dated September 28, 2023, by and between Cadmus Rich and the Registrant.

Exhibit 10.2 September 26, 2023 PERSONAL AND CONFIDENTIAL Dr. Cadmus Rich Re: Transition and Release Agreement Dear Dr. Rich: This letter confirms your resignation from employment with Aura Biosciences, Inc. (the “Company”), effective November 7, 2023. As you know, your employment relationship with the Company is governed by your offer letter with the Company dated October 6, 2017 (the “Offer Lett

Employment Offer Letter, dated August 9, 2023, by and between Jill Hopkins and the Registrant (incorporate by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40971) filed on November 9, 2023)

Exhibit 10.1 August 8, 2023 Jill Hopkins 1408 Columbus Ave. Burlingame, CA. 94010 Re: Offer of Employment Dear Jill, Following up on our discussions, the following represents our offer regarding your employment by Aura Biosciences, Inc. (the “Company”) as a full-time, “at will” employee. Your title and position will be Chief Medical Officer and President of Research and Development, and you will r

11,000,000 Shares Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268105 Prospectus Supplement (To Prospectus Dated November 7, 2022) 11,000,000 Shares Common Stock We are offering 11,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “AURA.” On November 6, 2023, the last reported sale price for our common stock on The Nasdaq Global Ma

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma Positive Clinical Efficacy Updates of Bel-sar for Early-Stage Cho

Exhibit 99.1 Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma Positive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial with Suprachoroidal Administration Presented at AAO 2023 Preliminary Data from Ph

Regulation FD Disclosure, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission

Subject to completion, dated November 6, 2023

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268105 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell

Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Exhibit 99.2 Corporate Presentation November 2023 Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as may , anticipate , believe , could', expect , should , plan , intend , estimate , wil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 (September 26, 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 (September 26, 2023) Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorp

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments J. Jill Hopkins, M.D., Appointed as Chief Medical Officer and President of Research & Development Mark Plavsic, Ph.D., Appointed as Chief Technology Officer

EX-99.1 Exhibit 99.1 Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments J. Jill Hopkins, M.D., Appointed as Chief Medical Officer and President of Research & Development Mark Plavsic, Ph.D., Appointed as Chief Technology Officer BOSTON, MA – October 2, 2023 – Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-l

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Strengthened Clinical and Regulatory Leadership Team with Key Appointments Start-up Activities for the Global Phase 3 Trial On

Exhibit 99.1 Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Strengthened Clinical and Regulatory Leadership Team with Key Appointments Start-up Activities for the Global Phase 3 Trial Ongoing with Release of Drug Product Manufactured with Commercial Process and First Patient Expected to be Dosed in 2H 2023 BOSTON, MA – Au

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2023 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

,k UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40971 AURA BIOSCIENCES, INC.

Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Corporate Presentation August 2023 Exhibit 99.2 Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "may", "anticipate", "believe", "could', "expect", "should", "plan", "intend", "estimat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Aura Biosciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40971 AURA BIOSCIENCES, INC.

Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Corporate Presentation May 2023 Exhibit 99.2 Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "may", "anticipate", "believe", "could', "expect", "should", "plan", "intend", "estimate",

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission Fil

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights U.S. Food and Drug Administration (FDA) Guidance in Type C Meeting Supports Global Phase 3 Trial in Early-stage Choroidal Melan

Exhibit 99.1 Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights U.S. Food and Drug Administration (FDA) Guidance in Type C Meeting Supports Global Phase 3 Trial in Early-stage Choroidal Melanoma Enrollment Complete in Phase 2 Trial in Choroidal Melanoma Using Suprachoroidal Route of Administration BOSTON, MA – May 11, 2023 – A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 3, 2023 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission F

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The summary of the general terms and provisions of the registered securities of Aura Biosciences, Inc. (the “Company,” “we,” “us,” and “our”) set forth below does not purport to be complete. It is subject to and qualified in its entirety by reference to our Tenth Amended

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for t

Exhibit 99.1 Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Pri

As filed with the Securities and Exchange Commission on March 15, 2023

S-8 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40971 AURA BIOSCIENCE

List of Subsidiaries of Registrant

Exhibit 21.1 List of Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation or Organization Aura Biosciences Securities Corporation Massachusetts Aura Biosciences B.V. Netherlands

Filing Fee Table

EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Aura Biosciences, Inc.

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration at the Macula Society 46t

Exhibit 99.1 Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration at the Macula Society 46th Annual Meeting Boston, MA – Feb. 16, 2023 – Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company deve

Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Corporate Presentation February 2023 Exhibit 99.2 Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "may", "anticipate", "believe", "could', "expect", "should", "plan", "intend", "estim

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 16, 2023 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commissio

AURA / Aura Biosciences Inc / CITADEL ADVISORS LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Aura Biosciences, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (the “Shares”) (Title of Class of Securities) 05153U107

AURA / Aura Biosciences Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment

SC 13G 1 aurabiosciences13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aura Biosciences, Inc. (Name of Issuer – as specified in its charter) Common Stock, $0.00001 par value per share (Title of Class of Securities) 05153U107 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of thi

AURA / Aura Biosciences Inc / Arix Bioscience plc - SC 13G/A Passive Investment

SC 13G/A 1 d442764dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aura Biosciences, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 05153U107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Ch

AURA / Aura Biosciences Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - AURA BIOSCIENCES, INC. Passive Investment

SC 13G/A 1 p23-0665sc13ga.htm AURA BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aura Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05153U107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement)

JOINT FILING AGREEMENT

EX-99.1 2 tm234008d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a statement on Schedule 13G (including amendments thereto) with respect to the shares of common stock, par value $0.00001, of Aura Biosciences, Inc., and further agrees t

AURA / Aura Biosciences Inc / Chiesi Ventures, Inc. - SC 13G/A Passive Investment

SC 13G/A 1 tm234008d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aura Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05153U107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement)

Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Corporate Presentation January 2023 Exhibit 99.1 Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "may", "anticipate", "believe", "could', "expect", "should", "plan", "intend", "estima

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 6, 2023 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commission

AURA / Aura Biosciences Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - AURA BIOSCIENCES, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aura Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05153U107 (CUSIP Number) December 5, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant

CZOO / Cazoo Group Ltd / Matrix Capital Management Company, LP - AURA BIOSCIENCES, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aura Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) G2007L105 (CUSIP Number) John Kaleba Matrix Capital Management Company LP Bay Colony Corporate Center 1000 Winter Street, Suite 4500 Waltham, MA 02451 E

Underwriting Agreement, dated as of November 30, 2022, by and between the Company, SVB Securities, Cowen and Evercore ISI, as representatives of the several underwriters named therein

Exhibit 1.1 Execution Version 6,700,000 Shares AURA BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT November 30, 2022 SVB SECURITIES LLC COWEN AND COMPANY, LLC EVERCORE GROUP L.L.C. As Representatives of the several Underwriters c/o SVB Securities LLC 53 State Street 40th Floor Boston, Massachusetts 02109 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Evercore G

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 30, 2022 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commissio

6,700,000 Shares Common Stock

424B5 1 d392034d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268105 Prospectus Supplement (To Prospectus Dated November 7, 2022) 6,700,000 Shares Common Stock We are offering 6,700,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “AURA.” On November 29, 2022, the last reported sale price for our commo

Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Corporate Presentation November 2022 Exhibit 99.1 Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "may", "anticipate", "believe", "could', "expect", "should", "plan", "intend", "estim

Subject to completion, dated November 30, 2022

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268105 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 30, 2022 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commissio

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Announced the Global Phase 3 Trial Design with Suprachoroidal Route of Administration of Belzupacap Sarotalocan in Early-Stage

Exhibit 99.1 Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Announced the Global Phase 3 Trial Design with Suprachoroidal Route of Administration of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma First Patient Dosed in the Phase 1 Study Evaluating Belzupacap Sarotalocan for the Treatment of Non-Muscle Invasive Bl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40971 AURA BIOSCIENCES, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commissio

VIA EDGAR

VIA EDGAR November 3, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

Open Market Sale AgreementSM, dated as of November 1, 2022, by and between the Registrant and Jefferies LLC

Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM November 1, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Aura Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common

Form of Senior Indenture between Registrant and one or more trustees to be named

EX-4.5 Exhibit 4.5 AURA BIOSCIENCES, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Aura Biosciences, Inc.

Power of Attorney (included in the signature pages to the Registration Statement)

S-3 Table of Contents As filed with the Securities and Exchange Commission on November 1, 2022 Registration No.

Form of Subordinated Indenture between Registrant and one or more trustees to be named

Exhibit 4.6 AURA BIOSCIENCES, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Cert

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022 Aura to Host Virtual Invest

Exhibit 99.1 Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022 Aura to Host Virtual Investor Day at 11:30 a.m. Eastern Time BOSTON, MA ? October 3, 2022 ? Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology com

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 2, 2022 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commission

Targeted Oncology Platform: Virus-Like Drug Conjugates (VDCs) Virus-Like Particles Conjugated to a Cytotoxic Payload to form the VDC VDCs can Recognize Tumor Associated HSPGs* Virus-Like Particle (VLP) Virus-Like Drug Conjugate (VDC) Cx Cytotoxic Dru

A Phase 2 Trial of Belzupacap Sarotalocan (AU-011) A First-in-Class Targeted Therapy for Choroidal Melanoma via Suprachoroidal Administration AAO 2022 October 2, 2022 Ivana K.

Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

Exhibit 99.2 October 2022 Corporate Presentation Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as may , anticipate , believe , could', expect , should , plan , intend , estimate , will

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 28, 2022 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commissi

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Exhibit 99.1 Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer BOSTON, MA ? September 28, 2022 ? Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today an

Lease Agreement, between Registrant and Ice Box, LLC, dated as of May 16, 2022 (incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40971) filed on August 11, 2022)

Exhibit 10.1 LEASE BETWEEN AURA BIOSCIENCES, INC., AS TENANT AND ICE BOX, LLC, AS LANDLORD 80 GUEST STREET, BRIGHTON, MA TABLE OF CONTENTS PAGE ARTICLE 1 BASIC DATA; DEFINITIONS 1 1.1 Basic Data 1 1.2 Additional Definitions 4 1.3 Enumeration of Exhibits 7 ARTICLE 2 PREMISES AND APPURTENANT RIGHTS 8 2.1 Lease of Premises 8 2.2 Appurtenant Rights and Reservations 8 2.3 Parking 10 2.4 Shuttle Service

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40971 AURA BIOSCIENCES, INC.

Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights On Track to Dose the First Patient in the Phase 1 Study Evaluating Belzupacap Sarotalocan (AU‑011) for the Treatment of Non-Mu

Exhibit 99.1 Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights On Track to Dose the First Patient in the Phase 1 Study Evaluating Belzupacap Sarotalocan (AU?011) for the Treatment of Non-Muscle Invasive Bladder Cancer in Q3 2022 On Track to Initiate Pivotal Trial in Early-Stage Choroidal Melanoma in Q4 2022 BOSTON, MA ? Augu

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Exhibit 99.1 Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer CAMBRIDGE, Mass.?(BUSINESS WIRE)? Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2022 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commission Fi

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma In th

Exhibit 99.1 Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation Compared to Pl

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 19, 2022 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commission Fi

Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking

ISOO 2022 New Developments in belzupacap sarotalocan (AU-011), an Investigational Virus-Like Drug Conjugate (VDC) in Ocular Oncology Exhibit 99.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 15, 2022 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commission Fi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 26, 2022 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commission Fil

Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

Exhibit 99.1 Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting CAMBRIDGE, MA ? May 26, 2022 ? Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pu

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2022 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40971 32-0271970 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40971 AURA BIOSCIENCES, INC.

Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights On Track to Meet Multiple Clinical Milestones for AU-011 in 2H 2022: Initiate Pivotal Trial in Choroidal Melanoma, Initiate Pha

Exhibit 99.1 Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights On Track to Meet Multiple Clinical Milestones for AU-011 in 2H 2022: Initiate Pivotal Trial in Choroidal Melanoma, Initiate Phase 1 Trial in Non-Muscle Invasive Bladder Cancer, and Submit IND for Choroidal Metastases CAMBRIDGE, MA ? May 12, 2022 ? Aura Biosciences

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 d309116ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40971 AURA BIOSCIENCE

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The summary of the general terms and provisions of the registered securities of Aura Biosciences, Inc. (the ?Company,? ?we,? ?us,? and ?our?) set forth below does not purport to be complete. It is subject to and qualified in its entirety by reference to our Tenth Amended

Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights On Track to Initiate Pivotal Trial in Choroidal Melanoma and Phase 1 Trial in Non-Muscle Invasive Bladder Cancer

Exhibit 99.1 Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights On Track to Initiate Pivotal Trial in Choroidal Melanoma and Phase 1 Trial in Non-Muscle Invasive Bladder Cancer with AU-011 in 2H 2022 Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Ch

List of Subsidiaries of Registrant

Exhibit 21.1 List of Subsidiaries of Registrant 1. Aura Biosciences Securities Corporation

Filing Fee Table

Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Aura Biosciences, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commission F

Tenth Amended and Restated Certificate of Incorporation of Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 of the Registrants’ Annual Report on Form 10-K (File No. 001-40971)).

Exhibit 3.1 TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AURA BIOSCIENCES, INC. Aura Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Aura Biosciences, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of

Amended and Restated Bylaws of Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 of the Registrants’ Annual Report on Form 10-K (File No. 001-40971)).

Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF AURA BIOSCIENCES, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may

As filed with the Securities and Exchange Commission on March 23, 2022

As filed with the Securities and Exchange Commission on March 23, 2022 Registration No.

AURA / Aura Biosciences Inc / CITADEL ADVISORS LLC - AURA BIOSCIENCES, INC. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Aura Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (the ?Shares?) (Title of Class of Securities) 05153U107

AURA / Aura Biosciences Inc / Advent Life Sciences LLP - FORM SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aura Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05153U107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

AURA / Aura Biosciences Inc / Arix Bioscience plc - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aura Biosciences, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 05153U107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

JOINT FILING AGREEMENT

EX-1 2 d300234dex1.htm EX-1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is

AURA / Aura Biosciences Inc / Lundbeckfond Invest A/S - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Aura Biosciences, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 05153U107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Presented Final Data from Phase 1b/2 Trial of AU-011 in Choroidal Melanoma at the American Academy of Ophthalmology’s Annual Me

Exhibit 99.1 Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Presented Final Data from Phase 1b/2 Trial of AU-011 in Choroidal Melanoma at the American Academy of Ophthalmology?s Annual Meeting Completed Initial Public Offering to Fund Pivotal Program for AU-011 in Choroidal Melanoma and Earlier Stage Oncology Pipeline CAMB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40971 AURA BIOSCIENCES, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2021 Aura Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40971 32-0271970 (State or Other Jurisdiction of Incorporation) (Commissio

AURA / Aura Biosciences Inc / CITADEL ADVISORS LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. )* Aura Biosciences, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 05153U107 (CUSIP Number) N

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Aura Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the un

AURA / Aura Biosciences Inc / Chiesi Ventures, Inc. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aura Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05153U107 (CUSIP Number) November 2, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a statement on Schedule 13G (including amendments thereto) with respect to the shares of common stock, par value $0.00001, of Aura Biosciences, Inc., and further agrees that this joint filing agreement be included

AURA / Aura Biosciences Inc / Arix Bioscience plc - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aura Biosciences, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 05153U107 (CUSIP Number) November 2, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa

Form of Lock-Up Agreement

EXHIBIT 99.3 Form of Lock-Up Agreement September , 2021 COWEN AND COMPANY, LLC SVB LEERINK LLC EVERCORE GROUP, L.L.C. As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o Evercore Group, L.L.C. 55 East 52nd Street New York, New York, 10055 Re: Aura B

AURA / Aura Biosciences Inc / Medicxi Growth I LP - SC 13D Activist Investment

SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* AURA BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05153U107 (CUSIP Number) Medicxi Growth I LP c/o Inte

Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended

EX-99.1 2 d259206dex991.htm EX-99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(f) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of the Issuer and further agree that this joint filing agreement be inc

JOINT FILING AGREEMENT PURSUANT TO RULE 13(d)-1(k)

Exhibit A JOINT FILING AGREEMENT PURSUANT TO RULE 13(d)-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.

CZOO / Cazoo Group Ltd / Matrix Capital Management Company, LP - AURA BIOSCIENCES, INC. Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Aura Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) G2007L105 (CUSIP Number) John Kaleba Matrix Capital Management Company LP Bay Colony Corporate Center 1000 Winter Street, Suite 4500 Waltham, MA 02451 Elea

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 AURA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001- 40971 32-0271970 (State or other jurisdiction of incorporation) (Commissio

5,400,000 Shares Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-260156 PROSPECTUS 5,400,000 Shares Common Stock This is the initial public offering of shares of our common stock. We are offering 5,400,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. Our common stock has been approved for listing on the Nasdaq Global Market under

Form S-8

As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.

2021 Stock Option and Incentive Plan, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.1 to the Registrant’s Registration Statement on Form S-8, as amended (File No. 333-260589)).

Exhibit 10.1 AURA BIOSCIENCES, INC. 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Aura Biosciences, Inc. 2021 Stock Option and Incentive Plan (as amended from time to time, the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Aura Biosciences, Inc. (t

As filed with the Securities and Exchange Commission on October 28, 2021.

As filed with the Securities and Exchange Commission on October 28, 2021. Registration No. 333? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aura Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 32-0271970 (State or other jurisdiction of incorporation or organization) (

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 AURA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 32-0271970 (State of incorporation or organization) (I.R.S. Employer Identification No.) 85 Bolton Street Camb

[signature page follows]

October 26, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

VIA EDGAR

VIA EDGAR October 26, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

Amendment No. 1

Table of Contents As filed with the Securities and Exchange Commission on October 25, 2021 Registration No.

Employment Offer Letter between the Registrant and Julie Feder, dated August 10, 2018 (incorporated by reference to Exhibit 10.9 of the Registrant’s Registration Statement on Form S-1 (File No. 333-260156) filed on October 25, 2021)

Exhibit 10.9 August 9, 2018 Julie B. Feder 85 Somerset Rd. Brookline, MA 02445 Re: Offer of Employment Dear Julie: Following up on our discussions, the following represents our offer regarding your employment by Aura Biosciences, Inc. (the ?Company?) as an ?at will? employee. Your title and position will be Chief Financial Officer and you will report to Elisabet de los Pinos, President and Chief E

Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on November 2, 2021, (File No. 001-40791)).

EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BY-LAWS OF AURA BIOSCIENCES, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pla

Form of Tenth Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-260156)).

Exhibit 3.2 TENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AURA BIOSCIENCES, INC. Aura Biosciences, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Aura Biosciences, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of

Form of Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-260156)) filed with the SEC on September 25, 2021)

Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PAR VALUE $0.00001 Certificate Shares Number **000000***************** ZQ00000000 ***000000**************** aura ****000000*************** *****000000************** 000000 AURA BIOSCIENCES, INC. ** Mr. Alexander INCORPORATED David Sample **** Mr. Alexander UNDER David Sample THE **** Mr. Alexander LAWS David

2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 of the Registrant’s Registration Statement on Form S-1 (File No. 333-260156) filed on October 25, 2021)

EX-10.4 8 d209588dex104.htm EX-10.4 Exhibit 10.4 AURA BIOSCIENCES, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Aura Biosciences, Inc. 2021 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Aura Biosciences, Inc. (the “Company”) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par

Employment Offer Letter between the Registrant and Cadmus Rich, dated October 14, 2017.

EX-10.10 14 d209588dex1010.htm EX-10.10 Exhibit 10.10 85 Bolton Street Cambridge, MA02140 617.500.8864 www.aurabiosciences.com October 6, 2017 Dr. Cadmus Rich Dear Dr. Rich: We are pleased to confirm the following terms in connection with your employment with Aura Biosciences, Inc. (the “Company”). 1. Position and Reporting. Your position with the Company will be Senior Vice President and Chief Me

Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.7 of the Registrant’s Registration Statement on Form S-1 (File No. 333-260156) filed on October 25, 2021)

Exhibit 10.7 AURA BIOSCIENCES, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [ ] by and between Aura Biosciences, Inc., a Delaware corporation, together with its subsidiaries, (the ?Company?), and [Director] (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as I

Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.5 of the Registrant’s Registration Statement on Form S-1 (File No. 333-260156) filed on October 25, 2021)

EX-10.5 9 d209588dex105.htm EX-10.5 Exhibit 10.5 AURA BIOSCIENCES, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Aura Biosciences, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or office

Senior Executive Cash Bonus Plan (incorporated by reference to Exhibit 10.6 of the Registrant’s Registration Statement on Form S-1 (File No. 333-260156) filed on October 25, 2021)

EX-10.6 10 d209588dex106.htm EX-10.6 Exhibit 10.6 AURA BIOSCIENCES, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of Aura Biosciences, Inc. (the “Company”) and its subsidiaries toward even higher achievement and business resul

Form of Underwriting Agreement

Exhibit 1.1 [•] Shares AURA BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT [•], 2021 COWEN AND COMPANY, LLC SVB LEERINK LLC EVERCORE GROUP L.L.C. As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o Evercore Group L.L.C. 55 East 52nd Street Ne

Employment Agreement between the Registrant and Elisabet de los Pinos, dated January 1, 2015, as amended on October 13, 2017 (incorporated by reference to Exhibit 10.8 of the Registrant’s Registration Statement on Form S-1 (File No. 333-260156) filed on October 25, 2021)

EX-10.8 12 d209588dex108.htm EX-10.8 Exhibit 10.8 22 January 2010 One Broadway 14th Floor Cambridge 02142 MA Re: Offer of Employment Dear Elisabet: On behalf of Aura Biosciences, Inc. (the “Company”), I am pleased to confirm our verbal offer of employment to you for the position of CEO starting on September 1st 2009, on an at-will basis. You shall have such powers and perform such duties as are cu

2021 Stock Option and Incentive Plan, and form of award agreements thereunder (incorporated by reference to Exhibit 10.3 of the Registrant’s Registration Statement on Form S-1 (File No. 333-260156) filed on October 25, 2021)

EX-10.3 7 d209588dex103.htm EX-10.3 Exhibit 10.3 AURA BIOSCIENCES, INC. 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Aura Biosciences, Inc. 2021 Stock Option and Incentive Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Cons

Goodwin Procter LLP

CORRESP 1 filename1.htm Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 October 25, 2021 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius and Joe McCann Re: Aura Biosciences, Inc. Registration

2018 Equity Incentive Plan, and form of award agreements thereunder.

Exhibit 10.2 AURA BIOSCIENCES, INC. 2018 EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Aura Biosciences, Inc. 2018 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the Admi

Goodwin Procter LLP

Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 October 8, 2021 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius and Joe McCann Re: Aura Biosciences, Inc. Amendment No. 1 to Draft Registration

Lease Agreement with Bolton Street Partners, LLC, dated June 9, 2011, as amended.

Exhibit 10.14 LEASE DATED: AS OF JUNE 9, 2011 BOLTON STREET PARTNERS, LLC, LESSOR AURA BIOSCIENCES, INC, LESSEE 85-95 BOLTON STREET, CAMBRIDGE, MASSACHUSETTS TABLE OF CONTENTS 1.0 Reference Data 1 2.0 Premises 4 2.1 Premises 4 2.2 Common Areas 4 2.3 As Is 4 2.4 Lessor’s Work 4 3.0 Term; Commencement Date 5 3.1 Term 5 4.0 Rent 5 4.1 Rent 5 5.0 Permitted Use 6 6.0 Taxes; Operating Expenses; Electric

List of Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries of Registrant None.

Exclusive Patent License Agreement with the National Institutes of Health, dated September 3, 2013 as amended.

Exhibit 10.11 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. THE NATIONAL INSTITUTES OF HEALTH PATENT LICENSE AGREEMENT - EXCLUSIVE COVER PAGE For the NIH internal u

License Agreement with Clearside Biomedical, Inc., dated July 3, 2019.

Exhibit 10.13 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. LICENSE AGREEMENT by and between CLEARSIDE BIOMEDICAL, INC. and AURA BIOSCIENCES, INC. July 3, 2019 Tabl

Ninth Amended and Restated Certificate of Incorporation of Registrant, as currently in effect.

Exhibit 3.1 NINTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AURA BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Aura Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. Tha

Exclusive License and Supply Agreement with LI-COR, Inc., dated January 31, 2014, as amended.

EX-10.12 8 d209588dex1012.htm EX-10.12 Exhibit 10.12 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Dated January 31, 2014 Bet

Power of Attorney (included on signature page).

Table of Contents As filed with the Securities and Exchange Commission on October 8, 2021 Registration No.

Fifth Amended and Restated Investors’ Rights Agreement (Incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-260156)).

EX-4.2 4 d209588dex42.htm EX-4.2 Exhibit 4.2 AURA BIOSCIENCES, INC. FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT March 18, 2021 TABLE OF CONTENTS Page SECTION 1 DEFINITIONS 3 1.1 Certain Definitions 3 SECTION 2 REGISTRATION RIGHTS 9 2.1 Demand Registration 9 2.2 Company Registration 11 2.3 Registration on Form S-3 12 2.4 Expenses of Registration 13 2.5 Registration Procedures 13 2.6 Inde

2009 Amended and Restated Stock Option and Restricted Stock Plan, and form of award agreements thereunder.

Exhibit 10.1 AURA BIOSCIENCES, INC. AMENDED AND RESTATED 2009 STOCK OPTION AND RESTRICTED STOCK PLAN 1. Purpose. Effective January 15, 2009, the Directors of Aura Biosciences, Inc. (the “Corporation”) adopted the “Aura Biosciences 2009 Long-Term Incentive Stock Option Plan” (“ Original Plan”). The Original Plan was approved by the stockholders of the Corporation on January 16, 2009. In accordance

Bylaws of Registrant, as currently in effect.

Exhibit 3.3 BY-LAWS of Aura Biosciences, Inc. (the “Corporation”) Article I - Stockholders 1. Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors. Any other proper business may be transacted at the annual meeting. If no date for the annual meeting is established or sai

LICENSE AGREEMENT by and between CLEARSIDE BIOMEDICAL, INC. AURA BIOSCIENCES, INC. July 3, 2019

EX-10.10 4 filename4.htm Exhibit 10.10 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. LICENSE AGREEMENT by and between CLEARSIDE BIOMEDICAL, INC. and AURA BIOSCIENCE

LEASE DATED: AS OF JUNE 9, 2011 BOLTON STREET PARTNERS, LLC, LESSOR AURA BIOSCIENCES, INC, LESSEE 85-95 BOLTON STREET, CAMBRIDGE, MASSACHUSETTS TABLE OF CONTENTS 1.0 Reference Data 1 2.0 Premises 4 2.1 Premises 4 2.2 Common Areas 4 2.3 As Is 4 2.4 Le

EX-10.11 5 filename5.htm Exhibit 10.11 LEASE DATED: AS OF JUNE 9, 2011 BOLTON STREET PARTNERS, LLC, LESSOR AURA BIOSCIENCES, INC, LESSEE 85-95 BOLTON STREET, CAMBRIDGE, MASSACHUSETTS TABLE OF CONTENTS 1.0 Reference Data 1 2.0 Premises 4 2.1 Premises 4 2.2 Common Areas 4 2.3 As Is 4 2.4 Lessor’s Work 4 3.0 Term; Commencement Date 5 3.1 Term 5 4.0 Rent 5 4.1 Rent 5 5.0 Permitted Use 6 6.0 Taxes; Ope

THE NATIONAL INSTITUTES OF HEALTH PATENT LICENSE AGREEMENT - EXCLUSIVE COVER PAGE

Exhibit 10.8 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. THE NATIONAL INSTITUTES OF HEALTH PATENT LICENSE AGREEMENT - EXCLUSIVE COVER PAGE For the NIH internal us

EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Dated January 31, 2014 LI-COR, Inc. Aura Biosciences, Inc.

EX-10.9 3 filename3.htm Exhibit 10.9 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Dated January 31, 2014 Between LI-COR, Inc

As confidentially submitted to the Securities and Exchange Commission on September 17, 2021 as Amendment No. 1 to the draft registration statement submitted on August 10, 2021. This Amendment No. 1 has not been publicly filed with the Securities and

Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 17, 2021 as Amendment No.

Goodwin Procter LLP

Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 September 17, 2021 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius and Joe McCann Re: Aura Biosciences, Inc. Draft Registration Statement on Fo

AURA BIOSCIENCES, INC. 2018 EQUITY INCENTIVE PLAN

Exhibit 10.2 AURA BIOSCIENCES, INC. 2018 EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Aura Biosciences, Inc. 2018 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the Admi

List of Subsidiaries of Registrant

EX-21.1 7 filename7.htm Exhibit 21.1 List of Subsidiaries of Registrant None.

BY-LAWS Aura Biosciences, Inc. (the “Corporation”) Article I - Stockholders

EX-3.3 3 filename3.htm Exhibit 3.3 BY-LAWS of Aura Biosciences, Inc. (the “Corporation”) Article I - Stockholders 1. Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors. Any other proper business may be transacted at the annual meeting. If no date for the annual meetin